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Extravascular Migratory Metastasis: the Mechanism for Melanoma Metastasis?
As a pathologist who has examined hundreds of cases of malignant
melanoma under the microscope, it is clear that angioinvasion ± the
identi®cation of unequivocal melanoma within a vessel ± is highly
unusual, despite the fact that many patients with melanomas
> 2 mm have metastatic disease at the time of the original biopsy. In
two related letters to the editor in this issue Dr. Raymond Barnhill
and Dr. Lugassy and colleagues from George Washington
University Medical Center provide clinical and in vitro data to
support a novel model of melanoma metastasis in which tumors
spread along the perivascular, rather than the intravascular, space. In
a study to determine the prognostic signi®cance of the presence of
melanoma cells in the perivascular space (termed `angiotropism'),
Barnhill and colleagues examined melanomas from 40 patients with
metastatic melanoma and 40 patients without metastatic melanoma
matched for age, gender, depth of melanoma, and anatomic site. In
the cohort of patients with metastatic disease, unequivocal
angiotropism was identi®ed in 16 cases compared with 6 cases in
patients with melanomas without metastatic disease. These results
strongly suggest that the presence of angiotropism is a prognostic
indicator for metastatic disease. In in vitro studies, Dr. Lugassy and
coworkers show that melanoma cells migrate along the abluminal
surface of endothelial tubules grown in culture. Strikingly, normal
human melanocytes also migrated towards new vessels and were
present in a pericytic location. The authors speculate that because
melanocytic cells are derived from mesenchymal tissue they may
compete with pericytes for the endothelial cell surface. The
observation that normal melanocytes occupy, and presumably
migrate along the perivascular space, suggests that this may be one
mechanism by which melanoblasts migrate from the neural crest to
the developing skin during embyrogenesis. Investigation into the
mechanisms of this novel method of tumor cell spread will likely
involve the determination of adhesion receptors that potentially
mediate melanoma cell and pericytic cell attachment. The in vitro
model described by Dr. Lugassy should lend itself well to
investigation into both the mechanisms and potential interventions
of angiotropism of malignant melanoma.
Cutting off the Blood Supply: How IL-18 Inhibits Melanoma Growth
Tumor-associated new vessel formation facilitates metastasis
through the supply of oxygen and nutrients to the growing tumor
and by providing a conduit for spread to distant sites. The
possibility of elimination of tumors by attacking their blood supply
captured headlines in 1994 when Judah Folkman and colleagues
published their observations on the effect of angiostatin on cancer
growth (O'Reilly et al, 1994). The concept of `strangling' a tumor
is highly appealing because of its potential for few if any systemic
side effects. In this issue Hiroshi Nagai and colleagues from Kobe
University provide hope that a similar point of attack may be
available for treatment of melanoma. Gene therapy for melanoma
has been used to express a variety of proteins primarily in an effort
to increase tumor immunogenicity. Nagai and colleagues describe a
profound effect on melanoma tumor vascularity following gene
therapy with IL-18. They fused the interferon-b signal sequence to
the mature IL-18 sequence and introduced the cDNA into B16F10
melanoma cells, cells known to be poorly immunogenic.
Transduced B16F10 cells injected into the ¯anks of syngeneic
mice showed a signi®cant reduction in tumor growth compared
with controls. Surprisingly, depletion of tumor-bearing mice of
natural killer and suppressor T-lymphocytes did little to abrogate
the effect of secreted IL-18 on tumor growth. However, treatment
of tumor-bearing mice with antibodies to interferon-g neutralized
the antitumor effect of IL-18. Interferon-g is known to induce the
expression of two proteins (IP-10 and Mig) that have potent
antiangiogenic properties and to suppress the production of
angiogenin, a protein with angiogenic properties. All three of
these proteins were altered in IL-18 expressing tumors. Finally,
histologic sections veri®ed a striking decrease in vascularity in IL-18
secreting tumors, which was eliminated with anti-IF-g antibodies.
These data provide an elegant explanation for the effect of IL-18 on
melanoma growth and an exciting avenue for therapeutic
intervention. Despite these very promising results, the recently
recognized ability of melanoma cells themselves to form blood
vessels in a blood vessel-poor environment requires one to insert a
cautionary word into the picture (Hendrix et al, 2002). This has
been termed `vasculogenic mimicry' by Hendrix and colleagues
who showed that highly aggressive melanomas have a pluripotential
embryonic-like phenotype and can form vascular structures in an
ischemic environment. Therefore strategies to limit vascularity of
melanoma may need to be focused on blood vessels native to the
tumor as well as vessels formed by melanoma mimicry.
Escape from Cell Death: Melanoma Finds a Way
Although melanoma progression from radial to vertical growth
phase and then to metastatic disease involves multiple mechanisms,
the ability of melanoma to suppress apoptosis ranks high on the list
of adaptive responses that foster melanoma growth. In this issue two
groups have examined two separate ways by which melanoma
escapes apoptotic signals. Eberle and colleagues from the Free
University of Berlin have shown that endothelin-1, a paracrine
signal peptide secreted from keratinocytes and a known mitogen for
human melanocytes, suppresses apoptosis in normal human
melanocytes and in melanoma cell lines that express the
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endothelin-B receptor. Even cell lines with low levels of
endothelin-B receptor expression showed an antiapoptotic response
to added endothelin. Further induction of endothelin-B receptor
expression in nonexpressing cells rendered them resistant to
apoptosis following endothelin treatment. Because metastatic
melanoma in tissue (but not in culture) exhibits up-regulated
expression of endothelin receptors, and because endothelin-1 is
secreted by vascular cells, endothelin produced and secreted by
endothelial cells may perform a critical function in melanoma
progression through suppression of apoptosis. The RAS RAF MEK
ERK MAP kinase pathway mediates cellular responses to growth
signals and has come to the forefront of attention in the community
of scientists investigating melanoma with the recognition that
BRAF, a serine threonine kinase that binds to ras, is mutated in
66% of melanomas (Davies et al, 2002). Ras is known to affect Fas-
mediated apoptosis in other cell types and in this issue Jean L.
Urquhart and colleagues from the University of Colorado have
shown that overexpression of N-ras results in resistance of melanoma
cells to Fas-mediate apoptosis. The primary mechanism appears to be
due to down-regulation of Fas surface receptor expression at the
transcriptional level by N-ras expressing cells. FLIP (¯ice inhibitory
protein), a downstream inhibitor of Ras-mediated apoptosis, and Fas
ligand, were unchanged. The downstream mechanisms by which ras
and endothelin suppress apoptosis in melanoma cells are still to be
determined but elucidation of the details of the downstream
regulators of ras and endothelin-mediated suppression of apoptosis
could lead to potential new therapies for melanoma.
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